Treatment of Locally Advanced Rectal Cancer: T3/T4, Involved or Threatened Circumferential Resection Margin, Locally Unresectable, or Medically Inoperable
This protocol addresses higher-risk locally advanced rectal cancer where the tumour's relationship to the surgical margin, extent of local invasion, or the patient's operative fitness places standard upfront resection out of reach.
Clinical Scenario
Patients qualifying for this protocol present with one or more of the following features:
- Clinical stage T3, any N — with an involved or threatened circumferential resection margin (CRM) on MRI
- Clinical stage T4, any N
- Locally unresectable disease
- Medically inoperable disease
CRM involvement is defined as tumour within 1 mm of the mesorectal fascia; for lower third rectal tumours, within 1 mm of the levator muscle; for anal canal lesions, invasion into or beyond the intersphincteric plane.
Treatment Approach
Total neoadjuvant therapy (TNT) is the only recommended approach for this population. TNT integrates systemic chemotherapy with radiotherapy — delivered in a structured sequence before surgery — rather than surgery first. The precise sequencing and choice of components within this framework depend on individual tumour characteristics and patient tolerance.
Treatment Goal
The primary aim is a complete clinical response — no evidence of residual disease on digital rectal examination, rectal MRI, and direct endoscopic evaluation. Response is formally assessed at restaging, approximately 8 weeks after completion of radiotherapy.
References
- T3, N any with involved or threatened CRM (by MRI); T4, N any or Locally unresectable or medically inoperable.
- Involved CRM: within 1 mm of mesorectal fascia; or, for lower third rectal tumors, within 1 mm from levator muscle; or, for anal canal lesions, invasion into or beyond the intersphincteric plane.
- For patients with higher-risk stage II or III rectal cancer, including cT3 lesions with involved or threatened CRM by MRI, cT4 lesions, and locally unresectable or medically inoperable disease, TNT is the only recommended approach.
- In the TNT approach, 12 to 16 weeks of chemotherapy are followed by chemoRT or short-course RT, restaging, and transabdominal resection.
- Alternatively, a TNT approach may start with chemoRT or short-course RT, followed by 12 to 16 weeks of chemotherapy, then restaging and transabdominal resection.
- Bolus 5-FU/leucovorin/RT is an option for patients not able to tolerate capecitabine or infusional 5-FU.
- Restaging (best tumor response 8 wk after completion of RT).
- In those patients who experience a complete clinical response to neoadjuvant therapy with no evidence of residual disease on digital rectal examination, rectal MRI, and direct endoscopic evaluation, a watch-and-wait nonoperative management approach may be considered in centers with experienced multidisciplinary teams.
View source ↗